Thông tin thuốc gốc
Chỉ định và Liều dùng
Acute myocardial infarction
Adult: In patients with persistent ST elevation or recent left Bundle Branch Block (initiate treatment immediately after onset of symptoms): As 5 mg (1,000 units)/mL reconstituted solution: <60 kg: 30 mg (6,000 units); ≥60-<70 kg: 35 mg (7,000 units); ≥70-<80 kg: 40 mg (8,000 units); ≥80-<90 kg: 45 mg (9,000 units); ≥90 kg: 50 mg (10,000 units). Max: 50 mg (10,000 units). All doses to be given as a single bolus inj over approx 5-10 seconds.
Suy gan
Severe: Contraindicated.
Hướng dẫn pha thuốc
Add the complete volume of water for inj (WFI) from the provided pre-filled syringe into the vial containing the powder for inj. Do not shake while reconstituting.
Tương kỵ
Incompatible with dextrose solutions.
Chống chỉ định
Hypersensitivity, bleeding disorder (at present or within 6 months), history of CNS damage (e.g. neoplasm, aneurysm, intracranial or spinal surgery), haemorrhagic diathesis, active internal bleeding, history of CVA, severe uncontrolled hypertension; major surgery, parenchymal organ biopsy or significant trauma (within 2 months); recent trauma to the head or cranium; prolonged cardiopulmonary resuscitation (>2 minutes) within 2 weeks; acute pericarditis and/or subacute bacterial endocarditis, acute pancreatitis, active peptic ulceration, arterial aneurysm, arterial or venous malformation, neoplasm with bleeding risk, active bleeding (except menstruation), suspected aortic dissection; history of haemorrhagic stroke or stroke of unknown origin; history of ischaemic stroke or TIA within 3 months; dementia. Severe hepatic impairment (e.g. hepatic failure, cirrhosis, portal hypertension [oesophageal varices], active hepatitis).
Thận trọng
Patient with significant hypertension on presentation (systolic blood pressure >160 mmHg or diastolic blood pressure >110 mmHg); history of chronic, severe, poorly controlled hypertension; cerebrovascular disease, recent gastrointestinal or genitourinary bleeding (within 10 days), increased risk of left heart thrombus (e.g. mitral stenosis or atrial fibrillation), recent IM inj (within 2 days), major surgery (<3 weeks), noncompressible vascular punctures, lumbar puncture (within 10 days), low body weight (<60 kg). Patient taking oral anticoagulants. Readministration of therapy. Patients should be transferred without delay to a coronary intervention capable facility for angiography and timely coronary intervention within 6-24 hours or earlier if needed (if used as a primary coronary recanalization treatment). Should not be given if primary PCI is scheduled according to the current relevant treatment guidelines. Avoid using rigid catheters, IM inj and nonessential handling of the patient. Elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypersensitivity reaction (e.g. angioedema, anaphylaxis, laryngeal oedema, urticaria, rash), cholesterol embolization, increased risk of thromboembolic events.
Gastrointestinal disorders: Gastrointestinal haemorrhage (e.g. gastric, gastric ulcer, mouth or rectal haemorrhage, haematemesis, melaena).
General disorders and administration site conditions: Inj or puncture site haemorrhage.
Renal and urinary disorders: Urogenital haemorrhage (e.g. haemorrhage urinary tract, haematuria).
Respiratory, thoracic and mediastinal disorders: Epistaxis.
Skin and subcutaneous tissue disorders: Ecchymosis.
Potentially Fatal: Coronary thrombolysis resulting in reperfusion arrhythmia; haemorrhage.
Chỉ số theo dõi
Monitor CBC, aPTT, ECG; signs and symptoms of bleeding especially on potential bleeding sites (e.g. infusion or puncture site); neurological status (e.g. intracranial haemorrhage), vital signs, hypersensitivity reaction.
Tương tác
Increased risk of bleeding with GPIIb/IIIa antagonists, drugs affecting coagulation or alters platelet function (e.g. clopidogrel, ticlopidine, LMWH).
Ảnh hưởng đến kết quả xét nghiệm
Alters coagulation and fibrinolytic activity test results.
Tác dụng
Description: Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native tissue plasminogen activator (t-PA) by modifications at 3 sites of the protein structure. It binds to fibrin and converts plasminogen to plasmin.
Metabolism: Metabolised primarily in the liver.
Excretion: Elimination half-life: Biphasic: 20-24 minutes (initial); 90-130 minutes (terminal).
Bảo quản
Store between 2-8°C or below 30°C. Protect from light.
Phân loại MIMS
Thuốc kháng đông, chống kết dính tiểu cầu & tiêu sợi huyết
Phân loại ATC
B01AD11 - tenecteplase ; Belongs to the class of enzymes. Used in the treatment of thrombosis.
Tài liệu tham khảo
Anon. Tenecteplase. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/07/2021.

Boehringer Ingelheim (N.Z.) Limited. Metalyse 40 mg, 50 mg Powder and Solvent For Infusion For Solution For Injection data sheet 03 December 2018. Medsafe. http://www.medsafe.govt.nz. Accessed 22/06/2021.

Buckingham R (ed). Tenecteplase. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/06/2021.

Joint Formulary Committee. Tenecteplase. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/06/2021.

Metalyse 8,000 units, 10,000 units Powder and Solvent for Solution For Injection (Boehringer Ingelheim International GmbH). European Medicines Agency [online]. Accessed 22/06/2021.

Metalyse Powder and Solvent For Solution For Injection (Boehringer Ingelheim Pharma GmbH & Co.). MIMS Singapore. http://www.mims.com/singapore. Accessed 22/06/2021.

Metalyse Powder and Solvent For Solution For Injection (Boehringer Ingelheim Pharma GmbH & Co.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 22/06/2021.

Tnkase (Genetech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 22/06/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Tenecteplase từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Metalyse
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in